PLIANT THERAPEUTICS INC

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

PLRX$0.80-1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity

AdditionalPaid-InCapital · AccumulatedOtherComprehensive Gain/(Loss) · AccumulatedDeficit · TotalStockholders’Equity
	Common Stock
Shares · Amount
Balance at December 31, 2023	59,921,002	$6	$972,973	$345	$(499,748)	$473,576
Issuance of common stock under benefit plans	397,540	—	1,879	—	—	1,879
Stock-based compensation expense	—	—	9,666	—	—	9,666
Net unrealized loss on short-term investments	—	—	—	(834)	—	(834)
Net loss	—	—	—	—	(46,955)	(46,955)
Balance at March 31, 2024	60,318,542	$6	$984,518	$(489)	$(546,703)	$437,332
Issuance of common stock under benefit plans	106,602	—	684	—	—	684
Stock-based compensation expense	—	—	10,644	—	—	10,644
Net unrealized loss on short-term investments	—	—	—	(128)	—	(128)
Net loss	—	—	—	—	(55,854)	(55,854)
Balance at June 30, 2024	60,425,144	$6	$995,846	$(617)	$(602,557)	$392,678
Issuance of common stock under benefit plans	424,359	—	543	—	—	543
Stock-based compensation expense	—	—	8,899	—	—	8,899
Net unrealized gain on short-term investments	—	—	—	1,465	—	1,465
Net loss	—	—	—	—	(57,763)	(57,763)
Balance at September 30, 2024	60,849,503	$6	$1,005,288	$848	$(660,320)	$345,822

Condensed Statements of Stockholders’ Equity

AdditionalPaid-InCapital · AccumulatedOtherComprehensive Loss · AccumulatedDeficit · TotalStockholders’Equity
	Common Stock
Shares · Amount
Balance at December 31, 2022	48,941,254	$5	$653,707	$(1,958)	$(338,412)	$313,342
Common stock issued in a public offering, net of offering expenses	9,583,334	1	269,914	—	—	269,915
Issuance of common stock under benefit plans	454,314	—	3,661	—	—	3,661
Stock-based compensation expense	—	—	11,923	—	—	11,923
Net unrealized gain on short-term investments	—	—	—	627	—	627
Net loss	—	—	—	—	(37,548)	(37,548)
Balance at March 31, 2023	58,978,902	$6	$939,205	$(1,331)	$(375,960)	$561,920
Public offering expenses	—	—	(133)	—	—	(133)
Issuance of common stock under benefit plans	243,783	—	334	—	—	334
Stock-based compensation expense	—	—	13,046	—	—	13,046
Net unrealized loss on short-term investments	—	—	—	(910)	—	(910)
Net loss	—	—	—	—	(41,192)	(41,192)
Balance at June 30, 2023	59,222,685	$6	$952,452	$(2,241)	$(417,152)	$533,065
Issuance of common stock under benefit plans	668,295	—	774	—	—	774
Stock-based compensation expense	—	—	10,362	—	—	10,362
Net unrealized gain on short-term investments	—	—	—	334	—	334
Net loss	—	—	—	—	(41,487)	(41,487)
Balance at September 30, 2023	59,890,980	$6	$963,588	$(1,907)	$(458,639)	$503,048

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.